Benitec Biopharma BNTC Q1 2027: Loss Narrows as BB-301 Trial Nears
As seen on the 24/7 Wall St. homepage on November 13, 2026.
R&D spending more than doubled to $8.6 million as Benitec pushes BB-301 toward a pivotal OPMD trial starting mid-2027, and the loss still came in narrower than expected. With $176.4 million in cash against a $317 million market cap, the stock now trades on clinical data.
Continue ReadingShow less
Benitec Biopharma reported a Q1 2027 GAAP net loss of $0.26 per share, beating the analyst consensus of $0.29. The company deliberately accelerated spending during the quarter to push its sole clinical asset, BB-301, toward a pivotal trial.
Research and development costs more than doubled to $8.6 million as the company funded BB-301, widening the net loss even as general and administrative expenses eased and interest income provided a partial offset.
Cash and equivalents stood at $176.4 million at quarter end, up 87% year over year, against a market cap of roughly $317 million. That cash position relative to the company's current burn rate gives Benitec a meaningful runway to reach the clinical readouts that will ultimately define the stock's trajectory.
Sponsored
BB-301 is a gene therapy targeting oculopharyngeal muscular dystrophy, a rare disease that causes progressive swallowing difficulty. Interim data presented at the ESGCT conference on October 28, 2026 showed a 100% responder rate across both cohorts, with no serious adverse events in any patient treated to date. CEO Jerel A. Banks described the results as evidence of "consistency and durability of the clinical benefit," and said the company looks forward to "confirming the pivotal study design in the first calendar quarter of 2027, with the study on track to commence in mid-2027."
BB-301 carries FDA Orphan Drug and Fast Track Designations as well as EMA Orphan Drug Designation, which streamline the regulatory path if the pivotal trial succeeds. With no revenue and a single asset in development, the stock is trading almost entirely on the clinical data. The next major catalyst is the finalized pivotal study design, expected before the end of Q1 2027, followed by trial initiation around mid-year.
Mentioned: BNTC